The authors reply
We appreciate the interest in our article shown in this letter by Taniguchi et al.1 We disagree with the suggestion that the dose of myeloperoxidase (MPO) inhibitor AZD5904 may have been insufficient. In our paper, Supplementary Figure S3 shows pharmacokinetic and in vitro studies that informed our choice of dosage.2 MPO inhibition in vivo was then confirmed, as shown in F igure 2h, with a marked reduction in peroxidase staining in neutrophils from mice given inhibitor, compared with control. Furthermore, the dose of the second MPO inhibitor AZM198 was the same as that used in a study showing a therapeutic effect in the nephrotoxic nephritis model.
Source: Kidney International - Category: Urology & Nephrology Authors: Fernanda Florez-Barros, Siobhan Bearder, Bengt Kull, Adrian Freeman, Attila M ócsai, Michael G. Robson Tags: Letter to the Editor Source Type: research